Qube Research & Technologies (QRT)
ABUS icon

Qube Research & Technologies (QRT)’s Arbutus Biopharma ABUS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-157,578
Closed -$758K – 3484
2025
Q4 		$758K Sell
157,578
-57,463
-27% -$258K ﹤0.01% 2663
2025
Q3 		$976K Sell
215,041
-152,989
-42% -$562K ﹤0.01% 2523
2025
Q2 		$1.14M Buy
368,030
+72,689
+25% +$241K ﹤0.01% 2411
2025
Q1 		$1.03M Sell
295,341
-94,996
-24% -$317K ﹤0.01% 2238
2024
Q4 		$1.28M Buy
390,337
+220,050
+129% +$809K ﹤0.01% 2069
2024
Q3 		$656K Buy
+170,287
New +$653K ﹤0.01% 2183
2024
Q1 		– Sell
-1,685
Closed -$4.21K – 4406
2023
Q4 		$4.21K Sell
1,685
-6,527
-79% -$12.8K ﹤0.01% 3739
2023
Q3 		$16.7K Sell
8,212
-8,966
-52% -$18.8K ﹤0.01% 3198
2023
Q2 		$39.5K Sell
17,178
-4,846
-22% -$12.6K ﹤0.01% 2095
2023
Q1 		$66.7K Buy
+22,024
New +$62.1K ﹤0.01% 2188
2021
Q3 		– Sell
-15,474
Closed -$47K – 2128
2021
Q2 		$47K Sell
15,474
-105,055
-87% -$325K ﹤0.01% 2025
2021
Q1 		$401K Sell
120,529
-263,768
-69% -$1.02M 0.01% 1305
2020
Q4 		$1.36M Buy
384,297
+343,223
+836% +$1.2M 0.02% 766
2020
Q3 		$129K Sell
41,074
-17,839
-30% -$54.3K ﹤0.01% 1466
2020
Q2 		$107K Buy
58,913
+14,994
+34% +$24.5K ﹤0.01% 1506
2020
Q1 		$44K Sell
43,919
-122,219
-74% -$331K ﹤0.01% 1021
2019
Q4 		$462K Buy
+166,138
New +$269K 0.01% 987

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ABUS Position: Q1 2026 in Review

Qube Research & Technologies (QRT) sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 157,578 shares — an estimated $758K sold.

Qube Research & Technologies (QRT) first reported a position in ABUS in Q4 2019 and held it in 17 quarters. The position peaked at $1.36M in Q4 2020. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Qube Research & Technologies (QRT) reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 157,578 Arbutus Biopharma shares in Q1 2026, an estimated $758K.
  • Qube Research & Technologies (QRT) first reported a position in Arbutus Biopharma in Q4 2019 and held it in 17 quarters.
  • Qube Research & Technologies (QRT)'s Arbutus Biopharma position peaked at $1.36M in Q4 2020.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.